Platelet resistance to antiplatelet drugs

Recent Patents on Cardiovascular Drug Discovery

Volumn 4, Issue 2, 2009, Pages 98-108

  Kumar, Ashwani ^a   Kao, John ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antiplatelet therapy; Aspirin; Clopidogrel; Percutaneous coronary intervention; Platelet resistance; Prasugrel and antiplatelet drugs

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PRASUGREL; PROSTAGLANDIN SYNTHASE; THIENOPYRIDINE DERIVATIVE; THROMBOXANE B2; TICAGRELOR; TICLOPIDINE; TRA SCH 530348; UNCLASSIFIED DRUG; DRUG DERIVATIVE;

ARTERY DISEASE; BLEEDING TIME; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONE AND PLATELET ANALYZER; CORONARY ARTERY DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG RESPONSE; ENTERIC COATED TABLET; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; IMPEDANCE AGGREGOMETRY; ISCHEMIA; LIGHT TRANSMISSION AGGREGOMETRY; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; PATENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPH PLATELET MAPPING SYSTEM; TREATMENT DURATION; ULTEGRA RAPID PLATELET FUNCTION ASSAY; VASODILATATION; DRUG EFFECT; MULTIDRUG RESISTANCE; THROMBOCYTE; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DRUG RESISTANCE, MULTIPLE; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 70149117757     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489009788452959     Document Type: Review

References (112)

1. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically. Can J Cardiol 1995; 11: 221-227.
2. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
3. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
4. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.
5. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin nonresponder. A pilot-study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403.
6. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-1007.
7. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1122-1126.
8. Ohmori T, Yatomi Y, Nonaka T, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: Involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006; 4: 1271-1278.
9. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 2004; 93: 456-458.
10. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
11. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events poststenting:results of the prepare post-stenting study. J Am Coll Cardiol 2005; 46: 1820-1826.
12. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST study. J Am Coll Cardiol 2005; 46: 1827-1832.
13. Bonello L, Camoin-jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator- stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance. J Am Coll Cardiol 2008; 51: 1404-1411.
14. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
15. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235.
16. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 1991; 63: 587-593.
17. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-787.
18. Cattaneo M. Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980-1987.
19. Patrono C. Aspirin resistance: Definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1: 1710-1713.
20. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-617.
21. Campbell CL, Steinhubl SR. Variability in response to aspirin: Do we understand the clinical relevance? J Thromb Haemost 2005; 3: 665-669.
22. Patrono C, García-Rodríguez LA, Landolfi R, Baigent C. Lowdose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383.
23. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005; 31: 174-183.
24. von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effects of 300, 600, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE Trial. Circulation 2005; 112: 2946-2950.
25. Angiolillo DJ, Capranzano P. Phramacotherapy of emerging novel platelet inhibitors. Am Heart J 2008; 156: S10-S15.
26. Murphy SA, Antman EM, Wiviott SD, et al. TRITON-TIMI 38 Investigators. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008; 29: 2473-2479.
27. Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008; 52: 1968-1977.
28. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
29. Ivandic BT, Schlick P, Staritz P, Kurz K, Katus HA, Giannitsis E. Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. Clin Chem 2006; 52: 383-388.
30. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85-92.
31. Geiger J, Teichmann L, Grossmann R, et al. Monitoring of clopidogrel action: Comparison of methods. Clin Chem 2005; 51: 957-965.
32. Grossmann R, Sokolova O, Schnurr A, et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004; 92: 1201-1206.
33. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet Function Analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312-319.
34. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: Comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005; 36: 1001-1005.
35. Mirkhel A, Peyster E, Sundeen J, et al. Frequency of aspirin resistance in a community hospital. Am J Cardiol 2006; 98: 577-579.
36. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006; 28: 315-322.
37. von Beckerath N, Pogatsa-Murray G, Wieczorek A, Sibbing D, Schomig A, Kastrati A. Correlation of a new point-of-care test with conventional optical aggregometry or the assessment of clopidogrel responsiveness. Thromb Haemost 2006; 95: 910-911.
38. van Werkum JW, van der Stelt CA, Seesing TH, Hackeng CM, ten Berg JM. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 2006; 4: 2516-2518.
39. Agarwal S, Coakley M, Reddy K, Riddell A, Mallett S. Quantifying the effect of antiplatelet therapy: A comparison of the platelet function analyzer (PFA-100) and modified thromboelasto-graphy (mTEG) with light transmission platelet aggregometry. Anesthesiology 2006; 105: 676-683.
40. Lau WC, Walker T, Ogilby D, et al. Evaluation of a bedside platelet function assay: Performance and clinical utility. Ann Card Anesth 2002; 5: 33-42.
41. Heptinstall S, Glenn J, May JA, Storey RF, Wilcox RG. Clopidogrel resistance. Catheter Cardiovasc Interv 2004; 63: 397-398.
42. Fontana P, Nolli S, Reber G, de Moerloose P. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006; 4: 813-819.
43. Frelinger AL III, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1 and cyclooxygenase-2-independent pathway: A 700-patient study of aspirin resistance. Circulation 2006; 113: 2888-2896.
44. Catella F, FitzGerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res 1987; 47: 647-656.
45. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002; 324: 71-86.
46. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
47. Grundmann KJK, Kleine B, Dichgans J, et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250: 63-66.
48. Wang JC, Aucoin-Barry D, Manuelian D, et al. Incidence of aspirin nonresponsiveness using the Ultegra rapid platelet function assay-ASA. Am J Cardiol 2003; 92: 1492-1494.
49. Serebruany VL, Malinin AI, Sane DC, et al. Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: The AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. Eur J Pharmacol 2004; 499: 315-324.
50. Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: Aspirin resistance or resistance to taking aspirin? Am Heart J 2004; 147: 293-300.
51. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817.
52. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113: 2906-2913.
53. Maree AO, Curtin RJ, Dooley M, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005; 46: 1258-1263.
54. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37: 2153-2158.
55. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-186.
56. Pulcinelli FM, Pignatelli P, Celestini A, et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004; 43: 979-984.
57. Hurlen M, Seljeflot I, Arnesen H. Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin. Thromb Res 2000; 99: 487-494.
58. Larsson PT, Wallen NH, Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation 1994; 89:1951-1957.
59. Kawasaki T, Ozeki Y, Igawa T, et al. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000; 31: 591-595.
60. Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 246-255.
61. Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: Constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 1998; 79: 691-705.
62. Minuz P, Fumagalli L, Gaino S, et al. Rapid stimulation of tyrosine phosphorylation signals downstream of G protein coupled receptors for thromboxane A2 in human platelets. Biochem J 2006; 400: 127-134.
63. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-1218.
64. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest 2001; 119: S39-S63.
65. Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87: 9383-9387.
66. Freedman JE. CD40-CD40L and platelet function: Beyond hemostasis. Circ Res 2003; 92: 944-946.
67. Hirsh J, Glynn MF, Mustard JF. The effect of platelet age on platelet adherence to collagen. J Clin Invest 1968; 47: 466-473.
68. Karpatkin S. Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Invest 1969; 48: 1083-1087.
69. Lakkis N, Dokainish H, Abuzahra M, et al. Reticulated platelets in acute coronary syndrome: A marker of platelet activity. J Am Coll Cardiol 2004; 44: 2091-2093.
70. McCabe DJ, Harrison P, Sidhu PS, Brown MM, Machin SJ. Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack. Br J Haematol 2004; 126: 861-869.
71. Guthikonda S, Lev EI, Patel R, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007; 5: 490-496.
72. Guthikonda S, Alivar CL, Vaduganathan M, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52: 743-749.
73. Macchi L, Christiaens L, Brabant S, et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T (GP Ia/IIa) and C-5T Kozak (GP Ib-alpha) polymorphisms. J Am Coll Cardiol 2003; 42: 1115-1119.
74. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001; 104: 2666-2672.
75. Pontiggia L, Lassila R, Pederiva S, Schmid HR, Burger M, Beer JH. Increased platelet-collagen interaction associated with double homozygosity for receptor polymorphisms of platelet GP Ia and GP IIIa. Arterioscler Thromb Vasc Biol 2002; 22: 2093-2098.
76. Quinn MJ, Topol EJ. Common variations in platelet glycoproteins: Pharmacogenomic implications. Pharmacogenomics 2001; 2: 341-352.
77. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: Effects on response to aspirin. Clin Pharmacol Ther 2003; 73: 122-130.
78. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the premier registry. Circulation 2006; 113: 2803-2809.
79. Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 1999; 25(Suppl 2):15-19.
80. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252: 233-238.
81. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-93.
82. Gladding P, Webster M, Zeng I, et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: The PRINC (Plavix Response in Coronary Intervention) Trial. J Am Coll Cardiol Interv 2008; 1; 612-619.
83. Kastrati A, von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004; 110: 1916-1919.
84. Collet JP, Silvain J, Landivier A, et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: The reload with clopidogrel before coronary angioplasty in subjects treated long term with dual antiplatelet therapy (RELOAD) study. Circulation 2008; 118: 1225-1233.
85. Aleil B, Jacquemin L, Poli FD, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention. Results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. J Am Coll Cardiol Interv 2008; 1: 631-638.
86. GRAVITAS: Gauging Responsiveness with A Verify Now Assay-Impact on Thrombosis and Safety. Available at: http://clinicaltrials.gov/ct2/show/ NCT00645918. Accessed on: December 30, 2008.
87. Mehta SR, Bassand JP, Chrolavicius S, et al. CURRENT-OASIS 7 Steering Committee. Design and rationale of CURRENT-OASIS 7: A randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 2008; 156: 1080-1088.
88. Taubert D, Kastrati A, Harlfinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004; 92: 311-316.
89. Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80: 486-501.
90. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166-171.
91. Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: Results from the interaction study. Arch Intern Med 2004; 164: 2051-2057.
92. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260
93. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148.e1-148.e5. doi:10.1016/ j.ahj.2008.09.017.
94. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52: 1557-1563.
95. Cattaneo M, Zighetti ML, Lombardi R, et al. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci USA 2003; 100: 1978-1983.
96. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207.
97. Lev EI, Patel RT, Maresh K, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention. The role of dual drug resistance. J Am Coll Cardiol 2006; 47: 27-33.
98. Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107: 45-49.
99. Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008; 52: 734-739.
100. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111: 3366-3373.
101. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin treated patients with coronary artery disease. Eur Heart J 2008; 29: 21-30.
102. Wiviott SD, Braunwald E, McCabe CH, et al., TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
103. Montaslescot G. TRITON-TIMI 38 Investigators. Prasugrel compared with clopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention. European Society of Cardiology (ESC) Congress 2008.
104. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29: 21-30.
105. A Study of the Antiplatelet Effects Comparing AZD6140 With Clopidogrel Responder and Non-Responders(RESPOND). Available at: http://clinicaltrials.gov/ct2/show/NCT00642811. Accessed on: December 30, 2008.
106. Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition PLATFORM. Available at: http://clinicaltrials.gov/ ct2/show/NCT00385138. Accessed on: December 30, 2008.
107. A Clinical Trial to Demonstrate the Efficacy of Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition PCI. Available at: http://clinicaltrials.gov/ct2/show/NCT00305162. Accessed on: December 30, 2008.
108. Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Acute Coronary Syndrome (TRA•CER). Available at: http://clinicaltrials.gov/ct2/show/NCT00527943. Accessed on: December, 2008.
109. Phillips, D.R., Andre, P., Homcy, C.J.: US20090012115A1 (2009).
110. Christie, D.J.: WO2008005771A2 (2008).
111. Phillips, D.R., Andre, P., Stephens, G.: US20087358091 (2008).
112. Santilli F, Rocca B, De Cristofaro R, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: Implications for aspirin "resistance". J Am Coll Cardiol 2009; 53: 667-677.